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Purpose of the study
To confirm in our cohort of patients the correlation
between hyperbilirubinaemia (defined as unconjugated
bilirubin >2 mg/dL and/or total bilirubin >2.5 mg/dL)
and elevated atazanavir (ATV) trough levels (i.e. >750 ng/
mL), and to assess the efficacy of a therapeutic drug mon-
itoring (TDM)-guided ATV dose reduction in order to
improve the clinical impact of this adverse event.
Methods
41 HIV-1 positive adult patients were included in this
study (30 males and 11 females; age = 44 ± 5.28 years;
body weight = 69 ± 11.3 kg). All of them received an
antiretroviral therapy (ART) including ATV 300 plus riton-
avir (RTV) 100 mg once daily and had an hyperbilirubi-
naemia, defined as above. ATV trough concentrations
(Ctrough) were measured for each patient by High Per-
formance Liquid Chromatography (HPLC).
Summary of results
In 31 out of 41 patients (75.6%), the ATV Ctrough was
>750 ng/mL. The correlation between ATV Ctrough and
bilirubinaemia was highly significant by linear regression
analysis for both unconjugated and total bilirubin (p <
0.0001). The 31 patients showing increased ATV Ctrough
and hyperbilirubinaemia were included in the second part
of our study. ATV daily dose was therefore reduced to 200
mg with RTV 100 mg, and ATV Ctrough and bilirubinae-
mia were reassessed after 15 days. ATV Ctrough was signif-
icantly lower after the dose reduction, passing from 1382
± 484.3 ng/mL to 929.2 ± 383.2 ng/mL (p < 0.0001); total
bilirubin passed from 3.3 ± 0.9 mg/dL to 2.3 ± 0.9 mg/dL
(p < 0.0001) and unconjugated bilirubin from 2.9 ± 0.9
mg/dL to 2 ± 0.8 mg/dL (p = 0.0001). Three months after
the ATV dose reduction, the immuno-virologic parame-
ters were also re-assessed; the rate of patients with unde-
tectable HIV-RNA did not show a statistically significant
difference (passing from 92.8% to 88.8%), whereas CD4
cell numbers showed a significant increase from 505.7 ±
288.6 cells/mmc to 602.6 ± 343.8 cells/mmc (p =
0.0016); the CD4 percentage, on the other hand, did not
differ significantly, passing from 24 ± 9.3% to 24.6 ±
9.5%.
Conclusion
Our data confirm a strong correlation between ATV
Ctrough and hyperbilirubinaemia, and more interest-
ingly, support a reduction in the ATV dosage from 300 mg
to 200 mg (both plus RTV 100 mg) once daily in hyperbi-
lirubinaemic patients with an ATV Ctrough >750 ng/mL.
By this approach, we were able to reduce significantly the
bilirubin levels, maintaining an optimal HIV suppression
and a satisfactory immunologic competence.
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